April M Jorge1,2, Na Lu3,4, Sarah F Keller3,4, Sharan K Rai3,4, Yuqing Zhang3,4, Hyon K Choi3,4. 1. From the Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. AMJorge@mgh.harvard.edu. 2. A.M. Jorge, MD, Graduate Assistant, Research Fellow, Massachusetts General Hospital, and Harvard Medical School; N. Lu, MPH, Research Assistant, Massachusetts General Hospital; S.F. Keller, MD, Rheumatology Fellow, Research Fellow, Massachusetts General Hospital, and Harvard Medical School; S.K. Rai, MSc, Research Assistant, Massachusetts General Hospital; Y. Zhang, DSc, Faculty, Harvard Medical School; H.K. Choi, MD, PhD, Professor, Harvard Medical School. AMJorge@mgh.harvard.edu. 3. From the Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. A.M. Jorge, MD, Graduate Assistant, Research Fellow, Massachusetts General Hospital, and Harvard Medical School; N. Lu, MPH, Research Assistant, Massachusetts General Hospital; S.F. Keller, MD, Rheumatology Fellow, Research Fellow, Massachusetts General Hospital, and Harvard Medical School; S.K. Rai, MSc, Research Assistant, Massachusetts General Hospital; Y. Zhang, DSc, Faculty, Harvard Medical School; H.K. Choi, MD, PhD, Professor, Harvard Medical School.
Abstract
OBJECTIVE: Systemic autoimmune rheumatic diseases (SARD) are associated with an increased risk of premature cardiovascular disease (CVD) and all-cause mortality. We examined the potential survival benefit of statin use among patients with SARD in a general population setting. METHODS: We conducted an incident user cohort study using a UK general population database. Our population included patients with a SARD as determined by Read code diagnoses of systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, dermatomyositis, polymyositis, mixed connective tissue disease, Behçet disease, or antineutrophil cytoplasmic antibodies-associated vasculitis between January 1, 2000, and December 31, 2014. We compared propensity score-matched cohorts of statin initiators and noninitiators within 1-year cohort accrual blocks to account for potential confounders, including disease duration, body mass index, lifestyle factors, comorbidities, and medication use. RESULTS: Of 2305 statin initiators, 298 died during the followup period (mean 5.1 yrs), whereas among 2305 propensity score-matched noninitiators, 338 died during the followup period (mean 4.8 yrs). This corresponded to mortality rates of 25.4/1000 and 30.3/1000 person-years, respectively. Statin initiation was associated with reduced all-cause mortality (HR 0.84, 95% CI 0.72-0.98). When we compared the unmatched cohorts, the statin initiators (n = 2863) showed increased mortality (HR 1.85, 95% CI 1.58-2.16) compared with noninitiators (n = 2863 randomly selected within 1-year cohort accrual blocks) because of confounding by indication. CONCLUSION: In this general population-based study, statin initiation was shown to reduce overall mortality in patients with SARD after adjusting for relevant determinates of CVD risk.
OBJECTIVE: Systemic autoimmune rheumatic diseases (SARD) are associated with an increased risk of premature cardiovascular disease (CVD) and all-cause mortality. We examined the potential survival benefit of statin use among patients with SARD in a general population setting. METHODS: We conducted an incident user cohort study using a UK general population database. Our population included patients with a SARD as determined by Read code diagnoses of systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, dermatomyositis, polymyositis, mixed connective tissue disease, Behçet disease, or antineutrophil cytoplasmic antibodies-associated vasculitis between January 1, 2000, and December 31, 2014. We compared propensity score-matched cohorts of statin initiators and noninitiators within 1-year cohort accrual blocks to account for potential confounders, including disease duration, body mass index, lifestyle factors, comorbidities, and medication use. RESULTS: Of 2305 statin initiators, 298 died during the followup period (mean 5.1 yrs), whereas among 2305 propensity score-matched noninitiators, 338 died during the followup period (mean 4.8 yrs). This corresponded to mortality rates of 25.4/1000 and 30.3/1000 person-years, respectively. Statin initiation was associated with reduced all-cause mortality (HR 0.84, 95% CI 0.72-0.98). When we compared the unmatched cohorts, the statin initiators (n = 2863) showed increased mortality (HR 1.85, 95% CI 1.58-2.16) compared with noninitiators (n = 2863 randomly selected within 1-year cohort accrual blocks) because of confounding by indication. CONCLUSION: In this general population-based study, statin initiation was shown to reduce overall mortality in patients with SARD after adjusting for relevant determinates of CVD risk.
Authors: Chi Chiu Mok; Chun Kwok Wong; Chi Hung To; Judy Po Shan Lai; Cheuk Sum Lam Journal: Arthritis Care Res (Hoboken) Date: 2011-06 Impact factor: 4.794
Authors: J Antonio Aviña-Zubieta; Alice Mai; Neda Amiri; Natasha Dehghan; Ju Ann Tan; Eric C Sayre; Hyon K Choi Journal: Arthritis Rheumatol Date: 2016-09-29 Impact factor: 10.995
Authors: Naomi Serling-Boyd; Kristin M D'Silva; Tiffany Yt Hsu; Rachel Wallwork; Xiaoqing Fu; Ellen M Gravallese; April M Jorge; Yuqing Zhang; Hyon Choi; Jeffrey A Sparks; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-11-30 Impact factor: 19.103
Authors: Der-Yuan Chen; Tatsuya Sawamura; Richard A F Dixon; José Luis Sánchez-Quesada; Chu-Huang Chen Journal: J Clin Med Date: 2021-05-06 Impact factor: 4.241
Authors: Kristin M D'Silva; Naomi Serling-Boyd; Rachel Wallwork; Tiffany Hsu; Xiaoqing Fu; Ellen M Gravallese; Hyon K Choi; Jeffrey A Sparks; Zachary S Wallace Journal: Ann Rheum Dis Date: 2020-05-26 Impact factor: 27.973